A very recent study revealed that high NRG1 expression predicts a decreased recurrence-free survival in HER2-overexpressing breast cancer patients compared to patients with low NRG1 expression [27], suggesting the clinical importance of NRG1. This evidence concerns the gene ERBB2 and breast carcinoma.